Literature DB >> 9326175

Cellular effects of hydroxyurea in Hb SC disease.

M H Steinberg1, R L Nagel, C Brugnara.   

Abstract

Hb S polymerizes in high-density Hb SC disease erythrocytes. We hypothesized that hydroxyurea -- perhaps independent of increasing Hb F -- might reduce the density of these cells. Six Hb SC disease patients were given 1000mg of hydroxyurea daily and blood counts, cell volumes, and cell density were followed for 12 months. There was an increase in MCV and reticulocyte MCV. A fall in absolute reticulocyte counts, high-staining ('stress') reticulocytes, serum bilirubin, and an increase in the ratio of mature red cell haemoglobin to reticulocyte haemoglobin, coupled with a rise in the haematocrit inferred a decrease in haemolysis and 'stress erythropoiesis'. An improvement in cell hydration was suggested by a reduction in reticulocyte mean cell haemoglobin concentration (CHCMr), red cells and reticulocytes with CHCM > 38, and decreased dense cell counts estimated by phthalate ester and Percoll-Larex gradients. After 4-5 months treatment, Hb F rose in a few patients but the overall difference in pre- and post-treatment Hb F was not significant. A decline in cell density should diminish the polymerization tendency of Hb S in Hb SC disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326175     DOI: 10.1046/j.1365-2141.1997.3173132.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Hydroxyurea inhibits the transactivation of the HIV-long-terminal repeat (LTR) promoter.

Authors:  M A Calzado; A MacHo; C Lucena; E Muñoz
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 2.  How I use hydroxyurea to treat young patients with sickle cell anemia.

Authors:  Russell E Ware
Journal:  Blood       Date:  2010-03-11       Impact factor: 22.113

3.  Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.

Authors:  R Borba; C S P Lima; H Z W Grotto
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

4.  Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease.

Authors:  Carly C Ginter Summarell; Vivien A Sheehan
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-17

5.  Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease.

Authors:  James G Taylor; Diana Ackah; Crystal Cobb; Nick Orr; Melanie J Percy; Vandana Sachdev; Roberto Machado; Oswaldo Castro; Gregory J Kato; Stephen J Chanock; Mark T Gladwin
Journal:  Am J Hematol       Date:  2008-01       Impact factor: 10.047

6.  Gum Arabic as fetal hemoglobin inducing agent in sickle cell anemia; in vivo study.

Authors:  Lamis Kaddam; Imad FdleAlmula; Omer Ali Eisawi; Haydar Awad Abdelrazig; Mustafa Elnimeiri; Florian Lang; Amal M Saeed
Journal:  BMC Hematol       Date:  2015-12-29

7.  Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia.

Authors:  Jeffrey D Lebensburger; Rakeshkumar J Patel; Prasannalaxmi Palabindela; Christina J Bemrich-Stolz; Thomas H Howard; Lee M Hilliard
Journal:  J Blood Med       Date:  2015-12-15

Review 8.  A Critical Balance: dNTPs and the Maintenance of Genome Stability.

Authors:  Chen-Chun Pai; Stephen E Kearsey
Journal:  Genes (Basel)       Date:  2017-01-31       Impact factor: 4.096

9.  TTP-like syndrome associated with hemoglobin SC disease treated successfully with plasma and red cell exchange.

Authors:  Sreenath Kodali; Preethi Ramachandran; Ivan N Richard; Jen-Chin Wang
Journal:  Leuk Res Rep       Date:  2019-07-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.